RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (South Korea), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (Australia), Conditional marketing approval (China), Orphan Drug (Japan)

Structure/Sequence

Sequence Code 10038962H

Source: *****

Sequence Code 10038967L

Source: *****

Clinical Trials associated with Burosumab-TWZA

NCT06202027

/ RecruitingNot Applicable

Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of CRYSVITA injection 10, 20, and 30mg, equivalent to in routine clinical settings

Start Date11 Aug 2023

Sponsor / Collaborator

Kyowa Kirin Korea Co., Ltd.

NCT05509595

/ CompletedPhase 2IIT

A Phase 2 Study of Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia

Background:
Fibrous dysplasia (FD) is a disorder that affects bone growth. Affected bone tissue is weakened, and people with FD are prone to deformities, fractures, and other problems. People with FD may also have low blood phosphate levels. This can make bones even weaker. Better treatments are needed.
Objective:
To test a study drug (burosumab) in people with FD who have low blood phosphate levels.
Eligibility:
People aged 1 year or older who have FD and low blood phosphate levels.
Design:
Participants will visit the NIH 3 times in 48 weeks. Each visit will last 5 to 7 days.
Participants will self-inject burosumab under the skin in their belly, upper arm, or thigh. They (or a caregiver) will do this at home 1 or 2 times a month. They will be trained in person on how to inject the drug. Home injections will be guided via telehealth.
During NIH visits, participants will have a physical exam with blood and urine tests. They will have x-rays of different parts of their body. They will have a radioactive tracer injected into their vein; then they will have a bone scan. They will have tests to assess their strength, walking, and movement. They will complete questionnaires about their pain, mobility, and fatigue levels.
Adult participants may have bone biopsies. These will be done under anesthesia with sedation. Small samples of FD-affected bone will be removed for study.
Between NIH visits, participants will go to a local laboratory for blood and urine tests.
Child participants will have an additional follow-up visit 2 weeks after the final NIH visit.

Start Date07 Dec 2022

Sponsor / Collaborator

National Institute of Dental & Craniofacial Research

NCT05357573

/ CompletedPhase 4

An Open-Label, Multi Center, Single-Cohort, Post-Marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With Tumor-Induced Osteomalacia (TIO)

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with TIO

Start Date07 Sep 2022

Sponsor / Collaborator

Kyowa Kirin Co., Ltd.

100 Clinical Results associated with Burosumab-TWZA

100 Translational Medicine associated with Burosumab-TWZA

100 Patents (Medical) associated with Burosumab-TWZA

279

Literatures (Medical) associated with Burosumab-TWZA

01 Dec 2025·Bone Reports

Effect of burosumab conversion on calciuria and nephrocalcinosis in children with XLH: A real-world cohort study

Article

Author: Chandrakumaran, Harry ; Filler, Guido ; Huang, Shih-Han Susan ; Stein, Robert ; Emile, Dougenie ; Babalola, Funmbi

Background:

Burosumab, a monoclonal antibody to fibroblast growth factor 23 (FGF23), is effective for X-linked hypophosphatemic rickets (XLH). Renal effects, particularly calciuria and nephrocalcinosis, remain incompletely characterized.

Methods:

In this retrospective cohort, 13 children with genetically confirmed XLH (7 females, 6 males; 0.6-16.3 years) were evaluated after conversion from conventional therapy to burosumab. Longitudinal changes in serum phosphate, TmP/GFR, TRP, 1,25(OH)₂D, intact parathyroid hormone (PTH), and urinary calcium/creatinine (Ca:Cr) were assessed. Hypercalciuria was defined using age-specific SI thresholds; Ca:Cr was also expressed as ×ULN (Ca:Cr divided by the age-specific upper limit).

Results:

Burosumab improved serum phosphate (p < 0.001), TmP/GFR (p < 0.001), and TRP (p = 0.007). Despite normalized phosphate handling, two patients developed de novo nephrocalcinosis. No child was hypercalciuric at washout or Day 14; two had ≥1 episode later. A repeated-measures analysis of log10(×ULN) showed no overall time effect from washout to Day 56 (F(4,29) = 1.66, p = 0.185). A larger decline in PTH correlated with higher Ca:Cr (p < 0.05), whereas 1,25(OH)₂D did not.

Conclusion:

Burosumab improves phosphate homeostasis in children with XLH, but a minority may develop hypercalciuria and nephrocalcinosis, potentially linked to PTH suppression. Vigilant biochemical and ultrasound monitoring-particularly early after conversion-and consideration of prophylaxis in high-risk cases are advisable.

01 Nov 2025·PEDIATRIC NEPHROLOGY

Toward lean body weight- and ECV-based dosing of burosumab: eliminating apparent sex differences in XLH therapy

Letter

Author: Filler, Guido ; Babalola, Funmbi

30 Sep 2025·Endocrine Connections

Burosumab prevents further height deficit in toddlers affected by XLH

Article

Author: Linglart, Agnès ; Mora, Stefano ; Berkenou, Jugurtha ; Audrain, Christelle ; Rothenbuhler, Anya ; Ertl, Diana-Alexandra ; Pitea, Marco ; Girerd, Barbara ; Lambert, Anne-Sophie ; Sala, Elisa

Background:

X-linked hypophosphatemia (XLH) is a rare disease caused by PHEX variants. Besides rickets, XLH leads to disproportionately short stature, which develops during the first months of life. Burosumab afforded minimal improvement of growth in children above the age of 4 years. No data are available on growth, including body mass index, of XLH children who started burosumab at a very young age, i.e., between 1 and 4 years.

Methods:

We performed a prospective follow-up of growth and other XLH-related outcomes in XLH children who started burosumab before the age of 4 years. We compared these children 1:2 with a historical cohort of XLH children who started vitamin D analogs and phosphate supplements before the age of 4 years.

Results:

We included 15 children treated with burosumab and 31 children treated with vitamin D analogs and phosphate supplements. In the burosumab-treated group, mean ± SD for age at therapy baseline was 2.1 ± 0.7 years (range: 1–2.9 years). They were treated with oral phosphate and active vitamin D for 1.7 ± 0.8 years before switching to burosumab. From birth to burosumab start, they presented a decline in height standard deviation score (SDS) from −0.3 ± 0.7 to −1.4 ± 0.8 (mean ± SD), respectively, P < 0.001. On burosumab, height SDS did not decline further during the first 2 years of treatment: mean ± SD 0.1 ± 0.6 (range: −0.7–1.3 SDS) after 1 year ( P = 0.16) and 0.0 ± 0.7 SD (range: −0.6–1.4 SDS) after 2 years ( P = 0.54). Burosumab did not correct the acquired height deficit, as children had a difference in height SDS of −1.5 SDS after 2 years of therapy when compared to birth length SDS ( P = 0.04). BMI SDS did not significantly change during the first 2 years on burosumab. Children treated with vitamin D analogs and phosphate supplements started treatment at a mean ± SD age of 1.3 ± 0.7 years (range: 0.1–3.0 years) and presented a continuous decline in height SDS of 0.7 ± 0.9 SDS (range: −2.6–1) during the first 2 years of therapy ( P < 0.001) and up to 4 years of age (−1.8 ± 0.9 SDS to −1.9 ± 0.9, respectively). BMI SDS increased by 0.5 ± 0.9 SDS (range: −0.6–1.9) during the same period ( P = 0.006).

Conclusion:

We present data from the largest pediatric XLH cohort of very young children treated with burosumab over a follow-up period of 2 years. Our data suggest that, in contrast to the combination of vitamin D analogs and phosphate supplements, burosumab prevents further height deficit in XLH children, even at a period of life associated with high growth velocity. In addition, burosumab prevents the early and excessive weight gain associated with the development of XLH in children.

Significance statement:

Most patients with X-linked hypophosphatemic rickets (XLH) present with short stature. This is the first large study on XLH children younger than 5 years treated with burosumab since a mean age of 2.1 years. We analyzed growth over a period of 2 years of therapy. Our data show that, in XLH toddlers, burosumab therapy prevents the further loss of height and the weight gain observed in patients treated with oral phosphate and active vitamin D therapy at the same age. As burosumab leads to better long-term outcomes in these children, we hope that our work will encourage the early use of burosumab and motivate further research in this field.

News (Medical) associated with Burosumab-TWZA

05 Nov 2025

·endpoints.news

Lilly partners with AI biologics company; Amgen ends gastric cancer study

Plus, news about Rigel Pharmaceuticals, Ultragenyx, Neurocrine Biosciences, TransThera, MoonLake Immunotherapeutics, Kelonia Therapeutics, Johnson & Johnson and Harmony Biosciences: 🖊️ Eli Lilly signs deal with XtalPi subsidiary: Lilly will get access to Ailux’s AI-powered bispecific antibody engineering platform, with rights to nominate an undisclosed number of targets. The deal could be worth up to $345 million across upfront and milestone payments. Ailux is a wholly-owned subsidiary of Chinese biotech XtalPi. — Ayisha Sharma 🔬 Amgen stops trial of stomach cancer drug : Head of R&D Jay Bradner said that the company stopped a trial studying bemarituzumab in combination with chemotherapy and Opdivo for patients with first-line gastric cancer due to “inadequate efficacy.” The decision follows an updated analysis of the drug in a separate but similar trial showing that its overall survival benefit when combined with chemotherapy waned over time. A third study, FORTITUDE-103, is testing bemarituzumab in combination with other anti-cancer therapies and has completed enrollment, Amgen said. — Max Bayer 🛑 Lilly terminates CNS work with Rigel: Lilly notified the biotech early last month that it would end their partnership on a preclinical CNS disease program. That partnership was part of a deal announced in 2021 . But the companies will still partner on ocadusertib, which is an RIPK1 inhibitor in a Phase 2a study in certain rheumatoid arthritis patients with moderate to severe disease. – Reynald Castaneda 💼 Ultragenyx divests rare disease drug royalties to Canadian pension fund: The biotech will receive $400 million from OMERS. This is in return for a further 25% of Ultragenyx’s royalty interest from Kyowa Kirin on US and Canadian sales of Crysvita. Proceeds from the deal should help fund four of Ultragenyx’s upcoming launches. — Ayisha Sharma 🖊️ Neurocrine signs deal with TransThera: In an agreement worth up to $881.5 million, Neurocrine will have the rights to develop and commercialize the Chinese company’s preclinical NLRP3 inhibitors for a variety of diseases outside Greater China. – Reynald Castaneda 🌕 Moonlake sells $75M in shares: The drugmaker will use the proceeds to support continued development of its nanobody candidate, sonelokimab, for inflammatory diseases, among other purposes. The offering is expected to close on Nov. 6. The company also reported Wednesday that its 16-week data from a Phase 2 trial showed that palmoplantar pustular psoriasis patients treated with sonelokimab had an average 64% reduction in the area and severity of their psoriasis. — Ayisha Sharma 🤝 Kelonia Therapeutics’ new collaborator: Kelonia will be working with Johnson & Johnson to develop in vivo CAR-T therapies. The biotech will contribute the technology to engineer immune cells directly in the body and J&J will pick the targets. Financial and scientific details were not disclosed, but the deal makes J&J the latest entrant in the red-hot field. Four other pharma companies — AbbVie, AstraZeneca, Bristol Myers Squibb and Gilead Sciences — have acquired startups working on in vivo cell therapies this year. — Ryan Cross ⏸️ Harmony Biosciences said it is pausing work on ZYN002 for a genetic disorder called 22q11.2 deletion syndrome. The synthetic cannabidiol gel previously failed in a Phase 3 fragile X syndrome study. – Reynald Castaneda

Phase 2Cell TherapyImmunotherapyClinical ResultPhase 3

30 Sep 2025

·www.einpresswire.com

April - June 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Acetaminophen-containing products Anaphylactic reaction FDA is evaluating the need for regulatory action. Aptryxol (desvenlafaxine) DaTscan (ioflupane I 123 injection) Desvenlafaxine extended-release tablets Effexor XR (venlafaxine extended-release) capsules Pristiq (desvenlafaxine) extended-release tablets Venlafaxine (venlafaxine hydrochloride) extended-release tablets False positive radioisotope investigation test result potentially secondary to a drug interaction with venlafaxine FDA is evaluating the need for regulatory action. Barium sulfate-containing products Entero Vu 24% (barium sulfate) oral suspension E-Z-Disk (barium sulfate) tablets Liquid E-Z-Paque (barium sulfate) oral suspension Readi-Cat 2 (barium sulfate) oral suspension Readi-Cat 2 Smoothie (barium sulfate) oral suspension Taglitol V (barium sulfate) oral suspension Varibar Honey (barium sulfate) oral suspension Varibar Nectar (barium sulfate) oral suspension Varibar Pudding (barium sulfate) oral paste Varibar Thin Honey (barium sulfate) oral suspension Varibar Thin Liquid (barium sulfate) oral suspension Anaphylactic reaction FDA is evaluating the need for regulatory action. Blincyto (blinatumomab) for injection Columvi (glofitamab-gxbm) injection Elrexfio (elranatamab-bcmm) injection Epkinly (epcoritamab-bysp) injection Imdelltra (tarlatamab-dlle) for injection Kimmtrak (tebentafusp-tebn) injection Lunsumio (mosunetuzumab-axgb) injection Talvey (talquetamab-tgvs) injection Tecvayli (teclistamab-cqyv) injection Progressive multifocal leukoencephalopathy FDA is evaluating the need for regulatory action. BRAF kinase inhibitors Braftovi (encorafenib) capsules Ojemda (tovorafenib) for oral suspension; tablets Tafinlar (dabrafenib) capsules; tablets Zelboraf (vemurafenib) tablets Gingival hypertrophy FDA is evaluating the need for regulatory action. Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Acute hepatic failure The "Warnings and Precautions" section of the labeling was updated in August 2025 to include information about liver injury. Example: Briumvi labeling Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection Central nervous system infection FDA is evaluating the need for regulatory action. Crexont (carbidopa and levodopa) extended-release capsules Dhivy (carbidopa and levodopa) tablets Duopa (carbidopa and levodopa) enteral suspension Rytary (carbidopa and levodopa) extended-release capsules Sinemet (carbidopa and levodopa) tablets Sinemet CR (carbidopa and levodopa) sustained-release tablets Stalevo (carbidopa, levodopa and entacapone) tablets Vyalev (foscarbidopa and foslevodopa) injection Seizure FDA is evaluating the need for regulatory action. Crysvita (burosumab-twza) injection Hypercalcemia The "Dosage and Administration", "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in August 2025 to include information about hypercalcemia. Crysvita labeling Dexmedetomidine-containing products Dexmedetomidine injection Precedex (dexmedetomidine hydrochloride) injection Igalmi (dexmedetomidine) sublingual film Diabetes insipidus FDA is evaluating the need for regulatory action. Dupixent (dupilumab) injection Ocular infections, irritations, and inflammation FDA is evaluating the need for regulatory action. Eprontia (topiramate) oral solution Qudexy XR (topiramate) extended-release capsules Qsymia (phentermine and topiramate) extended-release capsules Topamax (topiramate) tablets Topamax Sprinkle (topiramate) capsules Trokendi XR (topiramate) extended-release capsules Hypersensitivity FDA is evaluating the need for regulatory action. Gavreto (pralsetinib) capsules Chylothorax FDA is evaluating the need for regulatory action. Glucagon-like peptide-1 (GLP-1) receptor agonists Adlyxin (lixisenatide) injection Bydureon (exenatide) for extended-release injectable suspension Bydureon BCise (exenatide extended-release) injectable suspension Byetta (exenatide) injection Mounjaro (tirzepatide) injection Ozempic (semaglutide) injection Rybelsus (semaglutide) tablets Saxenda (liraglutide) injection Soliqua 100/33 (insulin glargine and lixisenatide) injection Trulicity (dulaglutide) injection Victoza (liraglutide) injection Wegovy (semaglutide) injection Xultophy 100/3.6 (insulin degludec and liraglutide) injection Zepbound (tirzepatide) injection Intestinal obstruction and fecal impaction FDA is evaluating the need for regulatory action. Imbruvica (ibrutinib) capsules; tablets; oral suspension Nail and nail bed conditions (excluding infections and infestations) FDA is evaluating the need for regulatory action. MEK inhibitors Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) Cotellic (cobimetinib) tablets Mekinist (trametinib) tablets; oral solution Mektovi (binimetinib) tablets Koselugo (selumetinib) capsules Gingival hypertrophy FDA is evaluating the need for regulatory action. Neffy (epinephrine nasal spray) Product storage error FDA is evaluating the need for regulatory action. Nurtec ODT (rimegepant) orally disintegrating tablets Zavzpret (zavegepant) nasal spray Anaphylactic reaction The "Contraindications" and "Warnings and Precautions" sections of the labeling were updated in August 2025 to include information about hypersensitivity reactions, including anaphylaxis. Example: Nurtec ODT labeling Rozlytrek (entrectinib) capsules; oral pellets Brugada syndrome FDA is evaluating the need for regulatory action. Sodium-glucose cotransporter-2 (SGLT2) inhibitors Fournier's gangrene FDA is evaluating the need for regulatory action. Teriparatide injection (a particular generic product) Device malfunction FDA is evaluating the need for regulatory action. Vizamyl (flutemetamol F18 injection) Anaphylactic reaction The "Warnings and Precautions" section of the labeling was updated in June 2025 to include information about anaphylaxis and other serious hypersensitivity reactions. Vizamyl labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalBiosimilar

28 Sep 2025

·pharma.economictimes.indiatimes.com

Asian and European drugmakers' branded drugs imported to the US market

Shanghai: U.S. President Donald Trump on Thursday unveiled a 100% tariff on imports of branded drugs from October 1, unless their producers had already broken ground on U.S. manufacturing plants . The European Union and Japan expressed confidence on Friday that they had secured limits on U.S. tariffs on pharmaceuticals . Below are some of the patented medicines from Asian and European drugmakers imported into the U.S. from overseas manufacturing sites in countries including China, Switzerland, Japan, Belgium and France, according to analysts and drugmaker statements. Lenvima Japan's Eisai's cancer drug Lenvima is manufactured in Japan, J.P.Morgan wrote in a recent note. Its US sales for the fiscal year ending March 31, 2025 were 229.6 billion yen ($1.53 billion). The company's US manufacturing site in Baltimore, Maryland, is responsible for producing a biodegradable implant used during surgeries, according to its website. Crystvita Kyowa Kirin 's X-linked hypophosphataemia drug Crysvita is manufactured in Japan, according to J.P.Morgan. In North America, the drug generated more than $1.3 billion net sales in its first four years on the market. It is building a biologics manufacturing facility in Sanford, North Carolina. Shingrix GSK 's vaccine Shingrix, used to prevent shingles, contributed 3.36 billion pounds ($4.50 billion) in sales in 2024. Its ingredients are manufactured in Belgium according to product labelling information provided in the National Institutes of Health platform and the U.S. FDA platform. Arexvy Arexvy is a vaccine developed by GSK to protect against Respiratory Syncytial Virus (RSV) in adults. It contributed 590 million pounds in sales in 2024. Its ingredients are made in Belgium and France according to product labelling information, given in NIH and U.S. FDA websites. Ozempic Novo Nordisk 's diabetes drug, Ozempic, contributed 120.34 billion DKK ($18.85 billion) in sales in 2024. It is manufactured in Denmark, according to the product labelling information given in NIH. In April, Novo Nordisk said it will invest 6.4 billion reais ($1.20 billion) in Brazil to boost production. The factory will cater to various product formats, including GLP-1 medicines such as semaglutide, the active ingredient in Ozempic and Wegovy. Wegovy Novo Nordisk's weightloss drug, Wegovy, contributed 58.21 billion DKK in sales in 2024. It is manufactured in Denmark, according to the product labelling information given in NIH. Kymriah Swiss drugmaker Novartis ' cell therapy Kymriah is manufactured at its Stein site in Switzerland and at its U.S. facility in Morris Plains, New Jersey, which produces CAR-T therapies for individual patients and clinical trials, according to the company's website. Its global sales for the first half of 2025 were $199 million. Entresto Novartis' heart-failure medicine Entresto is produced at Novartis manufacturing sites globally, with key stages of production taking place in Switzerland. Its global sales for the first half of 2025 were $4.62 billion. Novartis announced a $23 billion investment in April to build and expand 10 facilities in the U.S., including six new manufacturing plants and a research hub in San Diego. Comirnaty Germany's BioNTech and Pfizer co-developed COVID-19 vaccine Comirnaty. It is manufactured at BioNTech sites in Mainz and Marburg, Germany, and at Pfizer's facility in Puurs, Belgium, according to the company. BioNTech is the Marketing Authorization Holder for COMIRNATY and its adapted vaccines in the US, the EU, the UK and other countries. (Sources: NIH, FDA, company websites, company press releases, analyst notes)

VaccineDrug Approval

100 Deals associated with Burosumab-TWZA

External Link

KEGG	Wiki	ATC	Drug Bank
-	Burosumab-TWZA	M05BX05	DB14012

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
FGF23 positive Hypophosphatemia	South Korea	Kyowa Kirin Korea Co., Ltd.	17 Sep 2020
Oncogenic Osteomalacia	United States	Kyowa Kirin, Inc. /Sancuso/	18 Jun 2020
Rickets, Hypophosphatemic	Japan	Kyowa Kirin Co., Ltd.	20 Sep 2019
Osteomalacia	Canada	Kyowa Kirin Co., Ltd.	28 Jan 2019
Familial Hypophosphatemic Rickets	European Union	Kyowa Kirin Holdings BV	19 Feb 2018
Familial Hypophosphatemic Rickets	Iceland	Kyowa Kirin Holdings BV	19 Feb 2018
Familial Hypophosphatemic Rickets	Liechtenstein	Kyowa Kirin Holdings BV	19 Feb 2018
Familial Hypophosphatemic Rickets	Norway	Kyowa Kirin Holdings BV	19 Feb 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Pain	Phase 3	United States	Ultragenyx Pharmaceutical, Inc.	31 Jan 2018
Sebaceous of Jadassohn Nevus	Phase 3	United States	Ultragenyx Pharmaceutical, Inc.	31 Jan 2018
Hypophosphatemia	Phase 1	United States	Ultragenyx Pharmaceutical, Inc.	01 Jul 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESPE2024	Not Applicable	Familial Hypophosphatemic Rickets	19	Burosumab (X-linked hypophosphatemic rickets)	ettqcyxkmc(yapyuqxagq) = abrnpdxoks dajtpfmpcs (mbdoheudrm ) View more	Positive	16 Nov 2024
ESPE2024	Not Applicable	Familial Hypophosphatemic Rickets	24	Burosumab	xuglhabfkq(nwfclkztqe) = bxseemrwut uwrddtvtma (pvpsqtyxfr, 0.2) View more	Positive	16 Nov 2024
ENDO2024	Phase 3	Familial Hypophosphatemic Rickets PHEX mutation	-	Burosumab	plcwaflbfv(msxtmcltdg) = kqscrudsjr xaktsqcmck (yfsafryqrr ) View more	-	01 Jun 2024
NCT04146935 (CTgov)	Phase 4	Familial Hypophosphatemic Rickets	10	Burosumab Injection [Crysvita]	rgbnuuxokd(zidomaagbn) = nmrdaksrwv rplbsfaovn (nzxselzzsm, ljclolhjfn - auqswwjxmo) View more	-	24 Aug 2023
IMPROVEMENT IN PATIENT OUTCOMESFOLLOWING INITIATION OF BUROSUMAB INADULTS WITH XLH: A SINGLE CENTRE EXPERIENCE (WCO_IOF_ESCEO2023)	Not Applicable	Familial Hypophosphatemic Rickets FGF23	28	Burosumab	lvkhzaknus(qjgczuvzjf) = prbtdjzcjv pjhlxztelp (ydvokhosbr ) View more	Positive	04 May 2023
NCT03920072 (BUR02, WCO_IOF_ESCEO2023)	Phase 3	Familial Hypophosphatemic Rickets	35	Burosumab	uwfbudzvjv(cnrzrmybpg) = The most frequent of which were injection-site reactions, which resolved without requiring dose changes ruwecrezyb (qhftkeigue )	Positive	04 May 2023
NCT02304367 (UX023T-CL201, ENDO2022)	Phase 2	Oncogenic Osteomalacia FGF23	14	Burosumab	pivvdfezic(hlbvjrxqno) = lfcahjxosi kocchuavct (mkjceelzxm, 0.5)	Positive	01 Nov 2022
NCT02915705 (phase 3 trial, ESPE2022)	Phase 3	Familial Hypophosphatemic Rickets	62	Burosumab continuation group	oeebiytyoj(xbciovbjyq) = The mean change from baseline exceeded the MID for Pain Interference at weeks 64 and 88 and for Fatigue at week 64 in the burosumab continuation group, and for Pain Interference and Fatigue at week 88 in the crossover group kgfuuzmowh (swjcjvszar ) View more	Positive	15 Sep 2022
NCT02915705 (phase 3 trial, ESPE2022)	Phase 3	Familial Hypophosphatemic Rickets	62	Crossover group		Positive	15 Sep 2022
NCT02312687 (UX023-CL203, Pubmed) Manual	Phase 2	Familial Hypophosphatemic Rickets	20	Burosumab-TWZA	sulkpupjwa(ivpmysurtm) = dpwpeybuzx jmqocjqgki (jgkyuvneqt )	Positive	08 Sep 2022
NCT02537431 (phase 3, Pubmed)	Phase 3	Familial Hypophosphatemic Rickets \| Osteomalacia	14	Burosumab	lmvpteexoo(ylfpwbasgo) = dxwoxtxcps gtuilcioms (baaaejsfpw )	Positive	01 Jul 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis